Cohort Company News - MedTech Innovator

MiNDERA Corp closes Seed round and adds Andrew Offer to its Board

DateOct 12 2015

MiNDERA Corp. announces the close of its $1 million Seed financing round. Also, Andrew Offer, Managing Director at Scientific Health Development will be joining MiNDERA's Board of Directors following SHD's investment in the company.

MedAware’s Interview with Medgadget

DateOct 01 2015

Medgadget had a chance to speak with Dr. Gidi Stein, CEO and co-founder of MedAware, to learn more about the technology.

AventaMed raises €1.3m

DateSep 21 2015

AventaMed raised €1.3 million to run clinical trials on its device.

Mindera nominated for 2015 Diagnostics Startup of the Year

DateAug 27 2015

Diassess, Bikanta, Privail, and Mindera are nominated for the QB3 2015 Diagnostics Startup of the Year Award.

Lightpoint Medical and PartnerTech sign global manufacturing agreement

DateAug 17 2015

Lightpoint Medical's agreement with PartnerTech was signed by both parties in May, and is a major milestone for Lightpoint as they prepare for the launch of LightPath™ later in 2015. “

Lightpoint Medical Secures $2.6M Grant From National Cancer Institute

DateAug 06 2015

Lightpoint Medical received an R01 grant of $2.6M million from the US National Cancer Institute. This will support clinical trials of Lightpoint's EnLightTM molecular imaging technology in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK).

Vynca Wins Silicon Valley Boomer Venture Summit Business Plan Competition

DateJul 13 2015

Vynca won grand prize at the Silicon Valley Boomer Venture Summit’s Business Plan Competition, June 30 at Santa Clara University. Vynca won a $10,000 award for their care coordination and population management software platform for advanced care planning.

Lightpoint Medical wins UKBAA Award

DateJul 02 2015

Lightpoint Medical is honored to win the 2015 Award for Best Crowdfunding-Angel Investment of the Year from the UK Business Angels Association.

Admetsys Awarded Top Company at the 2015 Digital European Venture Summit

DateJun 02 2015

Admetsys has been awarded Top Company by Tech Tour and the European Venture Contest at the 2015 Digital Health Venture Forum and has been nominated to present its Smart Pancreas™ technology for hospitalized diabetics at the 2015 European Venture Summit in Düsseldorf, Germany.

Admetsys wins Worcester’s Five Minute Pitch Contest

DateApr 15 2015

Boston-based Admetsys was the winner of The Venture Forum's ninth annual Five-Minute-Pitch contest, held in Worcester Tuesday. Admetsys CEO Jeff Valk gave the winning presentation, earning the $2,500 first prize and the $1,000 audience choice award.

Briteseed vs. Surgical Perspective

DateMar 23 2015

Briteseed has raised $46,250 in cofounder contributions; significant business plan awards, including $73,500 in cash; $1.15 million raised in seed round using a convertible note.

Admetsys Wins Top Prize at SXSW Hatch Pitch competition

DateMar 16 2015

At the Hatch pitch competition five companies came away victorious including Admetsys. The winners received first round interview at Entrepreneurs Roundtable Accelerator; slots in two other accelerators; credits for services from Microsoft and Amazon; entrepreneur office hours.

Vixiar Medical Receives BioMaryland Development Award

DateFeb 09 2015

Vixiar Medical, Inc. announced today that it was awarded a $200,000 grant by the State of Maryland to accelerate the commercialization of its non-invasive congestive heart failure (CHF) device.

Fibralign beats 267 other startups at the 2014 MedTech Innovator competition

DateJul 14 2014

The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.

Fibralign set to bring new device option for secondary lymphedema

DateJun 26 2014

Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.